Nippon Shinyaku Co., Ltd. (TYO: 4516)

Japan flag Japan · Delayed Price · Currency is JPY
4,185.00
+49.00 (1.18%)
Dec 16, 2024, 3:45 PM JST
-14.03%
Market Cap 282.38B
Revenue (ttm) 154.27B
Net Income (ttm) 26.05B
Shares Out 67.38M
EPS (ttm) 386.72
PE Ratio 10.84
Forward PE 9.53
Dividend 124.00 (2.96%)
Ex-Dividend Date Mar 28, 2025
Volume 289,800
Open 4,168.00
Previous Close 4,136.00
Day's Range 4,123.00 - 4,208.00
52-Week Range 2,694.00 - 5,330.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Feb 7, 2025

About Nippon Shinyaku

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. Its Pharmaceuticals Business segment offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases. The company’s Functional Food Business segments provides health food ingredients, preservatives, protein preparations, and sports and supplements. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headq... [Read more]

Sector Healthcare
Founded 1911
Employees 2,213
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4516
Full Company Profile

Financial Performance

In 2023, Nippon Shinyaku's revenue was 148.26 billion, an increase of 2.83% compared to the previous year's 144.18 billion. Earnings were 25.85 billion, an increase of 13.32%.

Financial Statements

News

Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy

Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Read more here.

3 months ago - Seeking Alpha

Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel

Capricor Therapeutics partners with Nippon Shinyaku for European distribution of Duchenne muscular dystrophy treatment, deramiocel.

3 months ago - Seeking Alpha

EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm

Tuesday, Capricor Therapeutics Inc (NASDAQ: CAPR) entered into a binding term sheet with Nippon Shinyaku Co., Ltd. , a Japanese pharmaceutical company, for the commercialization and distribution in E...

3 months ago - Benzinga